Abstracts tagged "autoantibodies"

Abstract Number: 1307 • 2018 ACR/ARHP Annual Meeting
Autoantibodies in Idiopathic Interstitial Lung Disease and Interstitial Pneumonia with Autoimmune Features – a Prospective Study
Adelle S Jee^1,2, Jane F Bleasel^3,4, Stephen Adelstein^4,5,6, Lauren Troy^1,4, Helen Jo^1,4, Edmund Lau^1,4, Susanne Webster¹ and Tamera J Corte^7,8, ¹Respiratory and Sleep Department, Royal Prince Alfred Hospital, Sydney, Australia, ²Medicine Central clinical school, University of Sydney, Sydney, Australia, ³Rheumatology, Royal Prince Alfred Hospital, Sydney, Australia, ⁴Faculty of Medicine, University of Sydney, Sydney, Australia, ⁵Clinical Immunology and Allergy, Royal Prince Alfred Hospital, Sydney, Australia, ⁶Immunopathology Laboratory, South-west Sydney Pathology Service, Sydney, Australia, ⁷Royal Prince Alfred Hospital, Sydney, Australia, ⁸University of Sydney, Sydney, Australia
Background/Purpose: The detection of autoantibodies plays a vital role in the diagnosis of occult connective tissue disease (CTD) in patients with interstitial lung disease (ILD),…
Abstract Number: 1859 • 2018 ACR/ARHP Annual Meeting
The Prognostic Value of Autoantibody Isotypes for Predicting Therapeutic Responses to Methotrexate in Patients with Rheumatoid Arthritis
Daniela Sieghart¹, Alexander Platzer², Farideh Alasti², Paul Studenic³, Maresa Grundhuber⁴, Sascha Swiniarski⁴, Stephan Blüml², Helmuth Haslacher⁵, Josef S. Smolen⁶ and Günter Steiner¹, ¹Division of Rheumatology, Department of Internal Medicine III, Medical University Vienna, Austria, Vienna, Austria, ²Division of Rheumatology, Department of Internal Medicine III, Medical University Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Thermo Fisher Scientific, Freiburg, Germany, Freiburg, Germany, ⁵Department of Laboratory Medicine, Medical University Vienna, Vienna, Austria, ⁶Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
Background/Purpose: Rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) are the most specific diagnostic markers of rheumatoid arthritis (RA). Lately we showed that the determination…
Abstract Number: 2902 • 2018 ACR/ARHP Annual Meeting
Antibodies to PAD4 Drive Monocyte Activation and Differentiation into Osteoclast-like Cells
Pooja Naik¹, Jing Shi², Felipe Andrade³ and Erika Darrah⁴, ¹Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Department of Medicine/Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Agonistic antibodies to Peptidylarginine Deiminase 4 (PAD4) are hallmarks of a severe form of rheumatoid arthritis (RA) characterized by the most erosive joint damage…
Abstract Number: 392 • 2018 ACR/ARHP Annual Meeting
Autoantibody Profile and Clinical Characteristics in Patients with Idiopathic Inflammatory Myopathies
Sung Hae Chang¹, Sung Won Lee², Mi-Il Kang³, Mihye Kwon⁴, Chung-Il Joung⁴, Seong-Wook Kang⁵, In-Seol Yoo⁵, Seung-Cheol Shim⁵, Su-Jin Yoo⁶, In Ah Choi⁷, Ji Hyoun Kim⁸, Seung-Jae Hong⁹, Yeon-Ah Lee⁹, Sang Wan Chung¹⁰ and Jinhyun Kim¹¹, ¹Department of Internal Medicine, Department of Internal Medicine, College of Medicine, Soonchunhyang University, Cheonan, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Department of Rheumatology, Department of Internal Medicine, College of Medicine, Soonchunhyang University, Cheonan, Korea, Republic of (South), ³Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea, Republic of (South), ⁴Department of Internal Medicine, Konyang University hospital, Daejeon, Korea, Republic of (South), ⁵Division of Rheumatology, Department of Internal Medicine, Daejeon Rheumatoid & Degenerative Arthritis Center, Chungnam National University Hospital, Daejeon, Korea, Republic of (South), ⁶Rheumatology, Daejeon Rheumatoid & Degenerative Arthritis Center, Chungnam National University Hospital, Daejeon, Korea, Republic of (South), ⁷Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea, Republic of (South), ⁸Department of Internal Medicine, Chungbuk National University College of Medicine, Cheong-ju, Korea, Republic of (South), ⁹Rheumatology, Kyung Hee University Hospital, Seoul, Korea, Republic of (South), ¹⁰Division of Rheumatology, Department of Internal Medicine, Kyung Hee University Hospital, Seoul, Korea, Republic of (South), ¹¹Internal medicine, Daejeon Rheumatoid & Degenerative Arthritis Center, Chungnam National University Hospital, Deajeon, Korea, Republic of (South)
Background/Purpose: Autoimmune myositis (AIM) is a constellation of rare chronic disease with progressive muscle weakness. Several autoantibodies are found to be highly correlated with IIM…
Abstract Number: 1313 • 2018 ACR/ARHP Annual Meeting
Clinical Features and Timing of Studies in Interstitial Lung Disease with Autoimmune Disease Features: Do Autoantibody Panels Improve Diagnostic Yields and/or Increase Costs?
Josephine Wright¹, Dorota Odrobina², Mary Beth Scholand¹, Anne E. Tebo³ and Tracy M. Frech⁴, ¹Internal Medicine, University of Utah, Salt Lake City, UT, ²Internal Medicine, Rheumatology, University of Utah, Salt Lake City, UT, ³Pathology, University of Utah, Salt Lake City, UT, ⁴Division of Rheumatology, University of Utah, Salt Lake City, UT
Background/Purpose: The entity of interstitial lung disease with autoimmune disease features (ILD-AF) is increasingly gaining traction as condition that is best co-managed by pulmonologists and…
Abstract Number: 2010 • 2018 ACR/ARHP Annual Meeting
Anti-Endothelial Cell Antibodies in Pediatric Rheumatic Diseases
Rie Karasawa¹, Toshiko Sato¹, Megumi Tanaka¹, Mayumi Tamaki¹, Kazuo Yudoh¹ and James Jarvis², ¹Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, ²Pediatrics, University at Buffalo Jacobs School of Medicine & Biomedical Sciences, Buffalo, NY
Background/Purpose: Anti-endothelial cell antibodies (AECA) are antibodies detected in multiple autoimmune and inflammatory diseases. Increased levels of such antibodies may be involved in disease activity…
Abstract Number: 2953 • 2018 ACR/ARHP Annual Meeting
Disappearance of Autoantibodies in RA: Does It Occur with Current Treatment Strategies? a Long-Term Follow-up Study in Patients That Achieved DMARD-Free Sustained Remission
Debbie M. Boeters¹, Leonie E. Burgers¹, René E.M. Toes¹ and Annette H.M. van der Helm-van Mil^1,2, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Disease modifying antirheumatic drug (DMARD)-free sustained remission, the sustained absence of arthritis after cessation of all DMARD-therapy, is increasingly achievable with current treatment strategies.…
Abstract Number: 568 • 2018 ACR/ARHP Annual Meeting
Change in RF and Anti-CCP Isotype Levels in RA Patients Treated with Anti-TNF, Abatacept, Rituximab or Tocilizumab and Correlation with Clinical and Radiographic Outcomes: Data from a Randomized Trial
Renaud Felten¹, Marie-Alexandra Alyanakian², Lucienne Chatenoud², Jean Sibilia¹, Frédérique Gandjbakhch³, Cédric Lukas⁴ and Jacques-Eric Gottenberg¹, ¹University Hospital of Strasbourg, Department of Rheumatology, Strasbourg, France, ²Laboratoire d'Immunologie Biologique, Hôpital Necker-Enfants Malades, Paris, France, ³Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France, ⁴University Hospital Lapeyronie, Department of Rheumatology, Montpellier, France
Background/Purpose: In rheumatoid arthritis (RA), little is known about the prognostic relevance of the change in autoantibody (ab) levels. Seroconversion was reported to be associated…
Abstract Number: 1314 • 2018 ACR/ARHP Annual Meeting
Autoantibodies and Clinical Outcomes in Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases
Yuko Shirota¹, Tomonori Ishii², Tsuyoshi Shirai¹, Hiroshi Fujii¹ and Hideo Harigae¹, ¹Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, ²Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan
Background/Purpose: Pulmonary arterial hypertension (PAH) associated with SSc (SSc-PAH) has a substantially worse prognosis as compared to other connective tissue diseases (CTD)-PAH. Although SSc-PAH are…
Abstract Number: 2015 • 2018 ACR/ARHP Annual Meeting
Association of Anti-Ro52 Autoantibodies with Interstitial Lung Disease and More Severe Disease Manifestations in Juvenile Idiopathic Inflammatory Myopathies
Sara Sabbagh¹, Iago Pinal-Fernandez¹, Takayuki Kishi², Ira N. Targoff³, Frederick W. Miller², Lisa G. Rider² and Andrew Mammen^1,4, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²National Institute of Environmental Health Sciences, National Institutes of Health, Environmental Autoimmunity Group, Bethesda, MD, ³VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Neurology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Myositis specific autoantibodies (MSA) and myositis associated autoantibodies (MAA) found in adult and juvenile idiopathic inflammatory myopathies (JIIM) often confer a specific disease phenotype.…
Abstract Number: 577 • 2018 ACR/ARHP Annual Meeting
Expanded Autoantibody Profiles Predict Treatment Response to Biologic Therapy in Rheumatoid Arthritis
Ted R. Mikuls¹, Amrita Bath², Bryant R. England³, Michael J. Duryee⁴, Carlos D. Hunter⁴, Joel Kremer⁵, Dimitrios A. Pappas^6,7, William H. Robinson⁸, Jeffrey R. Curtis⁹ and Geoffrey M. Thiele¹⁰, ¹Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ²Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁴Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁵Albany Medical Center, Albany, NY, ⁶Columbia University, New York, NY, ⁷Corrona, LLC, Waltham, MA, ⁸Stanford University, Palo Alto, CA, ⁹University of Alabama at Birmingham, Birmingham, AL, ¹⁰University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Although biologics represent a major advance in rheumatoid arthritis (RA), many patients fail to achieve adequate responses to these agents. As previous studies have…
Abstract Number: 1331 • 2018 ACR/ARHP Annual Meeting
Moving from Dermatomyositis Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibody to Anti-Melanoma Differentiation-Associated Gene 5 Syndrome
Yves Allenbach¹, Yurdagul Uzunhan², Ségolène Toquet³, Gaëlle Leroux⁴, Laure Gallay⁵, Aude Rigolet⁶, Baptiste Hervier⁶, Nicolas Champtiaux⁶, Mathieu Vautier⁶, Perrine Guillaume⁶, Nicolas Limal⁷, Alain Meyer⁸, Christophe Deligny⁹, Bernard Bonnotte¹⁰, Hervé Devilliers¹¹, Sylvain Audia¹², Maxime Samson¹³, Amélie Servettaz¹⁴, Nathalie Costedoat¹⁵, David Saadoun¹⁶, elisabeth diot¹⁷, Alice Berezne¹⁸, Arsène Mékinian¹⁹, Kuberaka Mariampillai²⁰, Hilario Nunes² and Olivier Benveniste⁶, ¹Internal Medicine and Clinical Immunology, Sorbonne University - Assistance Public - Hopitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France, ²Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, ³Sorbonne Universités, UPMC Univ Paris 06, INSERM UMRS_974, CNRS FRE 3617, Center of Research in Myology., Paris, France, ⁴Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ⁵Internal Medicine, Université de Lyon - CHU Lyon, Lyon, France, ⁶Department of Internal Medicine and Clinical Immunology and Inflammation-Immunopathology-Biotherapy Department (I2B), Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, East Paris Neuromuscular Diseases Reference Center, Paris, France, ⁷Internal Medicine, APHP - Henri Mondor Hospital, Paris, France, ⁸15Département de Rhumatologie, Centre de Référence des Maladies Auto-immunes Rares, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ⁹Zobda Quitman Hospital, Rheumatology and Internal Medicine, Fort de France, Martinique, ¹⁰Dijon, Dijon, France, ¹¹Service de Médecine Interne et Maladies Systémiques, CHU de Dijon, Dijon, France, ¹²Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon; INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, Dijon, France, ¹³Dijon University Hospital, Dijon, France, ¹⁴Internal Medicine, CHU - Reims University, Reims, France, ¹⁵Internal Medicine, Paris Descartes Université - APHP, paris, France, ¹⁶Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier, Paris, France, ¹⁷Internal Medicine, Université Tours - CHU, Tours, France, ¹⁸Internal Medicine, CH Annecy, Annecy, France, ¹⁹Service de médecine interne. Hôpital Saint-Antoine., Paris, France, ²⁰Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Neuro-Musculaires Paris Est, Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Universitaire Pitié-Salpêtrière, Paris, France
Background/Purpose: Dermatomyositis (DM) is a heterogenous group of diseases ranging from skin limited disorders to non-specific auto-immune diseases with patients suffering from additional extra-cutaneous manifestations.…
Abstract Number: 2054 • 2018 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis, Changes in Autoantibody Levels Do Not Associate with Treatment Response, but Are a Reflection of Treatment Intensity
Emma de Moel¹, Veerle Derksen¹, LA Trouw¹, Holger Bang², Gerard Collée³, L.R. Lard⁴, Tom W.J. Huizinga⁵, Cornelia F. Allaart⁶, René E.M. Toes⁵ and Diane van der Woude⁵, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Orgentec Diagnostika GmbH, Mainz, Germany, ³Rheumatology, Haaglanden Medical Center Antoniushove, Leidschendam, Netherlands, ⁴Rheumatology, LUMC, Leiden, Netherlands, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Department of Rheumatology, LUMC, Leiden, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is characterized by the presence of autoantibodies like rheumatoid factor (RF), anti-cyclic citrullinated peptide-2 (anti-CCP2), & anti-carbamylated protein (anti-CarP) antibodies. It…
Abstract Number: 726 • 2018 ACR/ARHP Annual Meeting
Anti-Retinoblastoma Protein Antibody Is Protective Against Lupus Nephritis
Jessica Li¹, Andreas Goules², Daniel Goldman¹, Antony Rosen³, Livia Casciola-Rosen⁴ and Michelle Petri¹, ¹Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Retinoblastoma protein (RB) regulates nucleosome/chromatin structures and is linked to tumor suppression. It regulates the cell cycle by repression of E2F transcription factor and…
Abstract Number: 1339 • 2018 ACR/ARHP Annual Meeting
Myositis Specific Anti-Histidyl tRNA Synthetase (HisRS) Autoantibodies Display High Reactivity Against Hisrs Conformational Epitopes and Associate with Lung and Joint Involvement
Catia Fernandes-Cerqueira^1,2, Nuria Renard^1,2, Antonella Notarnicola^1,2, Edvard Wigren^1,2,3, Per-Johan Jakobsson^2,4, Susanne Graslund^1,2,3 and Ingrid E. Lundberg^1,2, ¹Department of Medicine, Division of Rheumatology, Karolinska Institutet, Stockholm, Sweden, ²Center for Molecular Medicine, Stockholm, Sweden, ³Structural Genomics Consortium, Stockholm, Sweden, ⁴Rheumatology Unit, Dept. of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Autoimmune myositis (rheumatic muscle inflammation) associated with interstitial lung disease (ILD) and arthritis is strongly correlated with the presence of anti-histidyl tRNA synthetase (HisRS)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].